Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

(2021) Fabrizio Vernieri et al.   JOURNAL OF HEADACHE AND PAIN

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Comparison of 3 Treatment Strategies for Medication Overuse Headache

(2020) Louise Ninett Carlsen et al.   JAMA Neurology

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

(2020) Armin Scheffler et al.   JOURNAL OF HEADACHE AND PAIN

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

(2020) Stephen D. Silberstein et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

(2020) Piero Barbanti et al.   HEADACHE

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in chronic migraine with medication overuse

(2019) Stewart J. Tepper et al.   NEUROLOGY

Targeting calcitonin gene-related peptide: a new era in migraine therapy

(2019) Andrew Charles et al.   LANCET

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY